Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study

Abstract Background High lipoprotein(a) [Lp(a)] levels have been re-evaluated as an independent risk factor for atherosclerotic vascular diseases. Methods We assessed whether serum Lp(a) levels can significantly influence long-term survival in subjects with an equal general cardiovascular (CV) risk...

Full description

Saved in:
Bibliographic Details
Published in:European journal of internal medicine 2017-01, Vol.37, p.49-55
Main Authors: Fogacci, Federica, Cicero, Arrigo Francesco Giuseppe, D'Addato, Sergio, D'Agostini, Laura, Rosticci, Martina, Giovannini, Marina, Bertagnin, Enrico, Borghi, Claudio
Format: Article
Language:English
Subjects:
Adult
Aged
Cardiovascular Diseases - blood
Cardiovascular Diseases - mortality
Cardiovascular mortality
Cohort Studies
Female
Humans
Internal Medicine
Italy
Kaplan-Meier Estimate
Lipoprotein(a)
Lipoprotein(a) - blood
Male
Middle Aged
Prognosis
Prospective Studies
Risk Factors
ROC Curve
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background High lipoprotein(a) [Lp(a)] levels have been re-evaluated as an independent risk factor for atherosclerotic vascular diseases. Methods We assessed whether serum Lp(a) levels can significantly influence long-term survival in subjects with an equal general cardiovascular (CV) risk profile. We prospectively evaluated a sample of 1215 adult subjects from the Brisighella Heart Study cohort (M: 608; F: 607; aged 40–69) who had no cardiovascular disease at enrolment. According to the CUORE project risk-charts (Italian-specific risk-charts), individuals were stratified into a low—(n = 865), an intermediate—(n = 275) and a high—(n = 75) cardiovascular risk groups. Kaplan–Meier 25-year survival analysis was carried out examining apart each class of risk and the log-rank statistic was used to estimate, when statistically possible, the survival time of the subjects stratified into quartiles of Lp(a). Results Subjects at high and intermediate CV risk aged 56–69 years (regardless of gender) and women aged 40–55 years with a low CV risk profile who had lower Lp(a) levels showed a significant benefit on CV mortality (P < 0.05 always) and, indicatively, on the estimated survival time (even P < 0.05). The ROC curves constructing for each CV risk group using Lp(a) as test-variable and death as state-variable identified serum Lp(a) as an independent long-term CV mortality prognosticator for subjects at high CV risk (AUC = 0.63, 95%CI [0.50–0.76], P = 0.049) and women with an intermediate CV risk profile (AUC = 0.7, 95%CI [0.52–0.79], P = 0.034). Conclusions In the light of our finding and at the best of the previous knowledge, dosing Lp(a) is confirmed as important in subjects at high or medium risk (even if in primary prevention for CV diseases), especially in women.
ISSN:0953-6205
1879-0828
DOI:10.1016/j.ejim.2016.08.018